Teva and jiangsu nhwa forge strategic partnership to promote patient access to austedo® in china

Shanghai & tel aviv, israel--(business wire)--teva pharmaceutical investments singapore pte ltd (tpis), a subsidiary of teva pharmaceutical industries ltd. (nyse and tase: teva) and jiangsu nhwa pharmaceutical co., ltd (“nhwa”) today announced it formed a partnership for the marketing and distribution of teva's austedo (deutetrabenazine) for the treatment of neurodegenerative and movement disorders - chorea associated with huntington's disease (hd) and tardive dyskinesia (td) in adults. the par.
TEVA Ratings Summary
TEVA Quant Ranking